Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies
Martín Ortiz-Genga(Universidade da Coruña), Lorenzo Monserrat(Universidade da Coruña), Juan Pablo Trujillo‐Quintero(Universidade da Coruña), Víctor M. Hidalgo-Olivares(Complejo Hospitalario Universitario de Albacete), Roberto Barriales‐Villa, Esther Zorio(Hospital Universitari i Politècnic La Fe), Eyal Nof(Tel Aviv University), Juan R. Gimeno(Hospital Universitario Virgen de la Arrixaca), Iria Duro-Aguado(Hospital Clínico Universitario de Valladolid), Ricardo Salgado‐Aranda(Hospital Universitario de Burgos), Michael Arad(Tel Aviv University), Hagith Yonath(Tel Aviv University), Juan Jiménez‐Jáimez(Hospital Universitario Virgen de las Nieves), Alicia Martín-Vila(University Hospital Complex Of Vigo), Sonia Marcos‐Alonso(Universidade da Coruña), Fernándo Domínguez(Hospital Universitario Puerta de Hierro Majadahonda), Marco Merlo(Universidade da Coruña), Matteo Dal Ferro(Azienda Ospedaliero Universitaria Ospedali Riuniti), Pablo García‐Pavía(Universidad Francisco de Vitoria), Davide Stolfo(Azienda Ospedaliero Universitaria Ospedali Riuniti), Julián Palomino(University Hospital Complex Of Vigo), Chiara Lanzillo(ASL Roma), Juan Pablo Ochoa(Universidade da Coruña), Diego García-Giustiniani(Universidade da Coruña), José L. Santomé(Universidade da Coruña), Enrique Lara‐Pezzi(Spanish National Centre for Cardiovascular Research), Vicente Climent(Hospital General Universitario de Alicante Doctor Balmis), Enrique García‐Campo(University Hospital Complex Of Vigo), Francisco Calvo(University Hospital Complex Of Vigo), Jorge Rodríguez-Garrido(Universidade da Coruña), Leonardo Calò(ASL Roma), Pilar Molina(Instituto Nacional de Toxicología y Ciencias Forenses), M. Paz Suárez-Mier(Instituto Nacional de Toxicología y Ciencias Forenses), Laura Padrón-Barthe(Spanish National Centre for Cardiovascular Research), María Luisa Peña Peña(Hospital Universitario Virgen del Rocío), Sofía Cuenca(Hospital Universitario Puerta de Hierro Majadahonda)
Cited by 472
Related Papers
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2013|3.4k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction
|European Heart Journal|2015|1.1k
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2021|1.1k